Novogen Limited (NASDAQ:KZIA) Given Average Recommendation of “Moderate Buy” by Brokerages

by · The Markets Daily

Shares of Novogen Limited (NASDAQ:KZIA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $25.80.

KZIA has been the subject of a number of research analyst reports. Lake Street Capital assumed coverage on Novogen in a research report on Thursday, June 11th. They issued a “buy” rating and a $32.00 target price for the company. BTIG Research assumed coverage on Novogen in a research note on Wednesday, July 1st. They issued a “buy” rating and a $34.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a report on Tuesday, April 21st. Laidlaw initiated coverage on Novogen in a research report on Wednesday, April 15th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Wall Street Zen cut Novogen from a “buy” rating to a “hold” rating in a report on Sunday, March 8th.

Read Our Latest Stock Analysis on Novogen

Novogen Price Performance

KZIA stock opened at $13.25 on Monday. The company’s 50-day moving average is $13.11 and its 200-day moving average is $9.50. Novogen has a 1 year low of $4.86 and a 1 year high of $17.40.

About Novogen

(Get Free Report)

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.

Featured Articles